Search research articles
Contact Us
Filters
Showing results (71-80 of 82) with videos related to
Page
of 9
Sort By:
The Lancet. Child & Adolescent Health
|
November 23, 2020
Acceptability, safety, and patterns of use of oral tenofovir disoproxil fumarate and emtricitabine for HIV pre-exposure prophylaxis in South African adolescents: an open-label single-arm phase 2 trial
Katherine Gill, Leigh Johnson, Janan Dietrich, et al.
AIDS and Behavior
|
May 26, 2026
A Narrative Review of Remote Biospecimen Collection Product and Implementation Considerations for Sexual Health Clinical Research
Keith J Horvath, Sarah E Rutstein, Ryan P Coyle, et al.
Journal of the International AIDS Society
|
October 9, 2020
An open-label, randomized crossover study to evaluate the acceptability and preference for contraceptive options in female adolescents, 15 to 19 years of age in Cape Town, as a proxy for HIV prevention methods (UChoose)
Katherine Gill, Anna-Ursula Happel, Tanya Pidwell, et al.
Plos One
|
June 23, 2023
Baseline preferences for oral pre-exposure prophylaxis (PrEP) or dapivirine intravaginal ring for HIV prevention among adolescent girls and young women in South Africa, Uganda and Zimbabwe (MTN-034/IPM-045 study)
Kenneth Ngure, Barbara A Friedland, Daniel W Szydlo, et al.
The Lancet. HIV
|
March 15, 2025
Safety, tolerability, and acceptability of long-acting injectable cabotegravir for HIV prevention in cisgender female adolescents (HPTN 084-01): a single-arm, open-label, phase 2b trial
Lynda Stranix-Chibanda, Erica L Hamilton, Julie Ngo, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
December 20, 2020
Tenofovir Diphosphate Concentrations in Dried Blood Spots From Pregnant and Postpartum Adolescent and Young Women Receiving Daily Observed Pre-exposure Prophylaxis in Sub-Saharan Africa
Lynda Stranix-Chibanda, Peter L Anderson, Deborah Kacanek, et al.
The Lancet. Infectious Diseases
|
July 29, 2014
Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study
Robert M Grant, Peter L Anderson, Vanessa McMahan, et al.
Plos Medicine
|
June 18, 2021
PrEP uptake, persistence, adherence, and effect of retrospective drug level feedback on PrEP adherence among young women in southern Africa: Results from HPTN 082, a randomized controlled trial
Connie Celum, Sybil Hosek, Mandisa Tsholwana, et al.
Communications Medicine
|
May 23, 2022
Implementation of a fully remote randomized clinical trial with cardiac monitoring
Jacob J Mayfield, Neal A Chatterjee, Peter A Noseworthy, et al.
The Lancet. HIV
|
October 28, 2023
Adherence, safety, and choice of the monthly dapivirine vaginal ring or oral emtricitabine plus tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis among African adolescent girls and young women: a randomised, open-label, crossover trial
Gonasagrie Nair, Connie Celum, Daniel Szydlo, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 82) with videos related to
Sort By:
Page
of 9
The Lancet. Child & Adolescent Health
|
November 23, 2020
Acceptability, safety, and patterns of use of oral tenofovir disoproxil fumarate and emtricitabine for HIV pre-exposure prophylaxis in South African adolescents: an open-label single-arm phase 2 trial
Katherine Gill, Leigh Johnson, Janan Dietrich, et al.
AIDS and Behavior
|
May 26, 2026
A Narrative Review of Remote Biospecimen Collection Product and Implementation Considerations for Sexual Health Clinical Research
Keith J Horvath, Sarah E Rutstein, Ryan P Coyle, et al.
Journal of the International AIDS Society
|
October 9, 2020
An open-label, randomized crossover study to evaluate the acceptability and preference for contraceptive options in female adolescents, 15 to 19 years of age in Cape Town, as a proxy for HIV prevention methods (UChoose)
Katherine Gill, Anna-Ursula Happel, Tanya Pidwell, et al.
Plos One
|
June 23, 2023
Baseline preferences for oral pre-exposure prophylaxis (PrEP) or dapivirine intravaginal ring for HIV prevention among adolescent girls and young women in South Africa, Uganda and Zimbabwe (MTN-034/IPM-045 study)
Kenneth Ngure, Barbara A Friedland, Daniel W Szydlo, et al.
The Lancet. HIV
|
March 15, 2025
Safety, tolerability, and acceptability of long-acting injectable cabotegravir for HIV prevention in cisgender female adolescents (HPTN 084-01): a single-arm, open-label, phase 2b trial
Lynda Stranix-Chibanda, Erica L Hamilton, Julie Ngo, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
December 20, 2020
Tenofovir Diphosphate Concentrations in Dried Blood Spots From Pregnant and Postpartum Adolescent and Young Women Receiving Daily Observed Pre-exposure Prophylaxis in Sub-Saharan Africa
Lynda Stranix-Chibanda, Peter L Anderson, Deborah Kacanek, et al.
The Lancet. Infectious Diseases
|
July 29, 2014
Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study
Robert M Grant, Peter L Anderson, Vanessa McMahan, et al.
Plos Medicine
|
June 18, 2021
PrEP uptake, persistence, adherence, and effect of retrospective drug level feedback on PrEP adherence among young women in southern Africa: Results from HPTN 082, a randomized controlled trial
Connie Celum, Sybil Hosek, Mandisa Tsholwana, et al.
Communications Medicine
|
May 23, 2022
Implementation of a fully remote randomized clinical trial with cardiac monitoring
Jacob J Mayfield, Neal A Chatterjee, Peter A Noseworthy, et al.
The Lancet. HIV
|
October 28, 2023
Adherence, safety, and choice of the monthly dapivirine vaginal ring or oral emtricitabine plus tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis among African adolescent girls and young women: a randomised, open-label, crossover trial
Gonasagrie Nair, Connie Celum, Daniel Szydlo, et al.
Page
of 9